Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tekmira Gets $11.2M Commitment from Alnylam | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tekmira Gets $11.2M Commitment from Alnylam

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tekmira Pharmaceuticals expects to receive $11.2 million during the next three years from partner Alnylam Pharmaceuticals for process development and manufacturing services. This commitment is part of the company’s manufacturing pact with Alnylam for the development of RNAi therapeutics through Phase II using Tekmira’s SNALP technology, including Alnylam’s clinical candidate ALN-VSP. The manufacturing and development funding is in addition to ongoing research activities between the two companies and in addition to milestone payments Alnylam is eligible to receive.

Dr. Mark J. Murray, Tekmira’s president and chief executive officer, said, “This manufacturing and development funding underlines Alnylam’s commitment to our partnership and to utilizing our leading SNALP delivery technology for multiple RNAi therapeutic product candidates. We have built a core competency around the design, development and manufacture of our SNALP formulations, including the manufacture of clinical products, and we provide this capability to our pharmaceutical partners to generate revenue to fund the development of our own proprietary products.”

In December 2008, Alnylam filed an IND with FDA for approval to begin human clinical trials for ALN-VSP, a potential treatment for liver cancers, including hepatocellular carcinoma and other solid tumors. ALN-VSP will be the first RNAi therapeutic using Tekmira’s SNALP technology to be evaluated in humans.

Under the partnership, Tekmira is eligible to receive as much as $16 million in milestones on each RNAi therapeutic advanced by Alnylam that utilizes Tekmira’s technology, as well as royalties on product sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics